Pediatric blood & cancer · 2026
Genetic Variants Associated With Oral Mucositis in Pediatric Patients With Acute Lymphoblastic Leukemia and Lymphoma Undergoing Chemotherapy.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jardim Luisa Comerlato, Botton Mariana Rodrigues, Curra Marina, Gabriel Amanda de Farias, Thieme Stefanie, Zieger Renata de Almeida, Martins Marco Antonio Trevizani, Matte Ursula da Silveira, Brunetto André Tesainer, Gregianin Lauro José, Roesler Rafael, Siebert Marina, Martins Manoela Domingues
Аннотация
BACKGROUND/OBJECTIVES: This study investigated the association between genetic variants and the occurrence of oral mucositis (OM) in pediatric patients with acute lymphoblastic leukemia (ALL) and lymphoma undergoing chemotherapy (CT).
METHODS: A retrospective observational longitudinal study was conducted, with daily assessment of OM using the World Health Organization scale and blood samples collected for DNA extraction. Genetic variants were analyzed through next-generation sequencing, using a gene panel focused on 67 coding regions within 20 genes.
RESULTS: Sixty-four pediatric patients were evaluated during 392 cycles of CT, with the most commonly used protocols being doxorubicin (DOXO) (34.2%), methotrexate (MTX) (27.8%), and cyclophosphamide (CTX) (17.3%). Approximately 65.8% of patients developed some degree of mucositis, with 34.7% showing ulcerative OM (Grades 2 or 3) and 9.2% presenting severe OM (Grade 3). Associations between genetic variants and OM were identified in MTX cycles (ABCC2, ABCC4, and GSTM1), CTX cycles (ABCC6, HSP90AA1, and ABCC1), and DOXO cycles (ABCC1, CYP2A7, and MTHFR).
CONCLUSION: This study suggests potential future treatment strategies, with the possibility of increasing efficacy, reducing toxicity, and improving survival rates in pediatric oncology patients.
METHODS: A retrospective observational longitudinal study was conducted, with daily assessment of OM using the World Health Organization scale and blood samples collected for DNA extraction. Genetic variants were analyzed through next-generation sequencing, using a gene panel focused on 67 coding regions within 20 genes.
RESULTS: Sixty-four pediatric patients were evaluated during 392 cycles of CT, with the most commonly used protocols being doxorubicin (DOXO) (34.2%), methotrexate (MTX) (27.8%), and cyclophosphamide (CTX) (17.3%). Approximately 65.8% of patients developed some degree of mucositis, with 34.7% showing ulcerative OM (Grades 2 or 3) and 9.2% presenting severe OM (Grade 3). Associations between genetic variants and OM were identified in MTX cycles (ABCC2, ABCC4, and GSTM1), CTX cycles (ABCC6, HSP90AA1, and ABCC1), and DOXO cycles (ABCC1, CYP2A7, and MTHFR).
CONCLUSION: This study suggests potential future treatment strategies, with the possibility of increasing efficacy, reducing toxicity, and improving survival rates in pediatric oncology patients.